Clinical Data Novo says high-dose Wegovy can cause 28% weight loss PharmaphorumNovo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.Metabolic & GLP-1Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: A year after Vertex’s big launch, pain drug research faces a pivotal momentNext: FDA turns to old drugs to address new diseases, persistent medical needs Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
